About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Therapy Optimization in Multiple Sclerosis (MS) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT00819000

Therapy Optimization in Multiple Sclerosis (MS)

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Lead sponsor: Teva Neuroscience, Inc.•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Teva Neuroscience, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female, 18 years of age or older, with a diagnosis of MS.
•Being treated with Glatiramer Acetate (GA) or (IFN)-β
•Receiving therapy from a participating Specialty Pharmacy

Exclusion Criteria

•Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
•Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
•Unlikely to be able to participate for the full two years of the study

Related studies

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

RECRUITINGPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · Relapsing Multiple Sclerosis

Nomad P-KAFO Study

NCT05644522 · Cerebrovascular Accident, Post-polio Syndrome, and more

RECRUITINGPhase 2

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399 · Multiple Sclerosis

RECRUITINGPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 29, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment2,878

Start dateDec 2008

Last updatedJan 29, 2013

Condition

Multiple Sclerosis

Locations shown

Teva Investigational Site

Swartz Creek, Michigan

Teva Investigational Site

Columbus, Ohio

Teva Investigational Site

Carnegie, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2013Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions